Viking Therapeutics shares fall more than 30% on disappointing obesity pill trial data

Viking Therapeutics shares plunged over 30% in premarket trading after mid-stage trial data for its oral obesity pill, VK2735, disappointed investors. While the drug showed up to 12.2% weight loss at three months, its efficacy and higher gastrointestinal side effect-driven discontinuation rates (28% over 13 weeks) were perceived as inferior to leading competitors like Eli Lilly's oral treatment. This outcome reinforces Eli Lilly and Novo Nordisk's market dominance and significantly diminishes Viking's appeal as a potential M&A target in the highly competitive oral obesity drug market.

Analysis

Viking Therapeutics (VKTX) shares experienced a significant premarket decline of over 30% following the release of disappointing mid-stage trial data for its oral obesity pill, VK2735. While the drug achieved up to 12.2% weight loss at the three-month mark, its competitive profile is severely undermined by a problematic side-effect profile and high discontinuation rates. Approximately 28% of trial participants discontinued the treatment over 13 weeks, primarily due to gastrointestinal issues, with 58% reporting nausea and 26% experiencing vomiting. This safety and tolerability data compares unfavorably with market leaders Eli Lilly (LLY) and Novo Nordisk (NVO), whose competing oral drugs demonstrated lower discontinuation rates over much longer trial durations. Specifically, Eli Lilly's orforglipron saw a 25% discontinuation rate over 72 weeks, a comparison that Mizuho's analyst labeled as making Viking's results look "inferior on almost all metrics." Consequently, this outcome significantly diminishes Viking's prospects of becoming a major competitor in the oral obesity market in the near-to-medium term and substantially reduces its appeal as a potential M&A target, thereby reinforcing the entrenched market dominance of Eli Lilly and Novo Nordisk.

Key Decisions for Investors

• Investors should significantly discount Viking Therapeutics' valuation, as the disappointing trial data severely weakens its competitive standing and reduces the probability of a near-term acquisition.
• The results reinforce the competitive moats of Eli Lilly and Novo Nordisk, supporting a bullish outlook on their continued dominance in the high-growth obesity drug market.
• For those invested in the broader biotech sector, this event highlights that tolerability and side-effect profiles, not just efficacy, are critical hurdles for challengers in the oral GLP-1 space.
• Monitor any future data from Viking regarding longer-term studies, as the company noted weight loss had not plateaued, but treat this potential upside with extreme caution given the high discontinuation rate and adverse event profile.